Back
Non-Moderated Poster Abstract
Eposter Presentation
https://storage.unitedwebnetwork.com/files/1237/fdf713f8087f3b9bbc4137b3e98c3340.pdf
Accept format: PDF. The file size should not be more than 5MB
https://storage.unitedwebnetwork.com/files/1237/ebc51da6e19542c8cb2e7072d520a436.jpg
Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB
 
Submitted
Abstract
Pilot Study on the Impact of Low-intensity Extracorporeal Shockwave Therapy (ESWT) of the Kidneys on Hypertension and Creatinine Levels in Chronic Kidney Disease Stage 3a and 3b Patients
Non-Moderated Poster Abstract
Clinical Research
Novel Advances: New Technology
Author's Information
5
No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.
Philippines
Sheldon Marllow Bulaong sheldonbulaong@gmail.com Veterans Memorial Medical Center Urology Quezon City Philippines *
Gavino Mercado sheldonbulaong@gmail.com VMMC Urology quezon city Philippines
Karl Marvin Tan sheldonbulaong@gmail.com VMMC urology quezon city Philippines
Eli Paulino Madrona sheldonbulaong@gmail.com VMMC Urology quezon city Philippines
Michael Eufemio Macalalag sheldonbulaong@gmail.com VMMC Urology Quezon city Philippines
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract Content
Low Intensity Extracorporeal Shock Wave Therapy (LI-ESWT) has been shown to enhance renal perfusion and stimulate cellular repair and angiogenesis. These mechanisms indicate that LI-ESWT may serve as a valuable adjunctive treatment for managing hypertension in patients with stage 3a and 3b chronic kidney disease (CKD). By improving blood flow and promoting kidney health, LI-ESWT could help regulate blood pressure and preserve or enhance renal function in this patient population.
This study included adult patients diagnosed with CKD stage III a/b, characterized by an estimated glomerular filtration rate (eGFR) of 30-59 ml/min/1.73 m², and hypertension defined as a blood pressure of 130/80 mmHg or greater. Eligible patients were those receiving treatment with one to three classes of antihypertensive medications. Selected patients underwent six sessions of LI-ESWT, delivered with an energy density of 0.1 to 0.3 mJ/mm² and a frequency of 1 to 3 Hz. Sessions were scheduled twice a week for three weeks. Blood pressure, creatinine levels, and eGFR were measured at baseline (pre-LI-ESWT) and at the 4th, 12th, 24th, and 48th weeks post-treatment.
The study enrolled 24 patients, predominantly male (23 males and 1 female), aged 60 to 77 years. Significant improvements were noted following LI-ESWT, with systolic blood pressure decreasing from a baseline range of 136-141 mm Hg to 121-125 mm Hg (p < 0.001), averaging a reduction of 15 mm Hg. Diastolic blood pressure also improved, dropping from 86-89 mm Hg to 79-84 mm Hg (p < 0.001), with a similar average decrease of 15 mm Hg. Furthermore, creatinine levels significantly decreased, from a baseline range of 142-173 mmol to 104-111 mmol (p < 0.001), with all patients achieving normal creatinine levels by the end of the study.
Preliminary findings indicate that LI-ESWT is an effective intervention for managing hypertension and improving renal function in patients with stage III a/b CKD. Further research with a larger and more diverse cohort is recommended to validate these results.
 
 
 
 
 
 
 
 
 
 
 
1792
 
Presentation Details
 
 
 
0